Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL712956

O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.c1ccc(COc2ccc(OCc3cccnc3)c(-c3nc4cccnc4[nH]3)c2)cc1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GPR132 Q9UNW8 7/20 0.45
PPARG P37231 2/20 0.44
ALOX5 P09917 1/20 0.44
PSEN1 P49768 1/20 0.44
LRRK2 Q5S007 4/20 0.43
CMKLR2 P46091 1/20 0.42
CMKLR1 Q99788 1/20 0.42
PTPN1 P18031 1/20 0.41
IKBKB O14920 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL709554 0.95 CYP3A4 (0.43) GPR132PPARGALOX5PSEN1LRRK2
SCHEMBL10206615 0.92 IKBKB (0.47) GPR132LRRK2IKBKBMEN1KMT2A
Trifluoroacetic Acid SCHEMBL711595 0.90 LRRK2 (0.43) PPARGALOX5PSEN1LRRK2
Trifluoroacetic Acid SCHEMBL713332 0.90 KMT2A (0.41) GPR132PTPN1MEN1KMT2A
Trifluoroacetic Acid SCHEMBL711107 0.90 GPR132 (0.43) GPR132PPARGALOX5PSEN1CMKLR2
Trifluoroacetic Acid SCHEMBL709855 0.89 SMO (0.41) PPARGLRRK2PTPN1MEN1KMT2A
Trifluoroacetic Acid SCHEMBL711971 0.88 CYP3A4 (0.43) LRRK2
Trifluoroacetic Acid SCHEMBL712591 0.87 PDE5A (0.41) GPR132PPARGPPARDPPARA
Trifluoroacetic Acid SCHEMBL711385 0.87 CYP3A4 (0.39) GPR132LRRK2PPARDPPARARAB9A
SCHEMBL10206607 0.87 CYP3A4 (0.51) ALOX5RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK GPR132 2062/4885PPARG 991/4885ALOX5 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.